Amarin R&D gets cozy with Pfizer; PolyMedix shares jump on antibiotic data;

Image removed. @FierceBiotech: Roche CEO says pharma is facing a turbulent "perfect storm." More | Follow @FierceBiotech

Image removed. @JohnCFierce: Here's a smart idea: In-license drugs tested/proved in humans to treat dogs/cats. But were the humans treated humanely? Release | Follow @JohnCFierce

Image removed. @RyanMFierce: NIH pumping $416M into sequencing projects over next 4 years, highlights new funding for rare diseases. Story | Follow @RyanMFierce

Image removed. @MaureenFierce: Roche and Pfizer launch pharma's first official Google+ pages. Story | Follow @MaureenFierce

> Amarin's decision to move its R&D operations in Connecticut closer to the Pfizer ($PFE) campus in Groton has helped fuel rumors of a possible takeover. Amarin's AMR101 has attracted considerable attention for its market potential. Story

> Radnor, PA-based PolyMedix saw its shares surge on the news it garnered encouraging interim data from its mid-stage study of the PMX-30063 defensin-mimetic antibiotic, indicating "all dosing arms in the study were both safe and effective in treating patients with acute bacterial skin and skin structure infections." Release

> With its revenue from Provenge falling well behind initial estimates, Dendreon ($DNDN) has opted to sell its share of the royalty rights in the hepatitis C drug Victrelis for $125 million. Story

> Israel's Clal Biotechnology is boosting its stake in Biocancell. Story

> Scientists say that a new vaccine for the rare but highly lethal ebola virus looked promising in a recent mouse study, guarding 80% of the rodents. Story

Pharma News

Image removed. FiercePharma: Chinese gov't OKs plan for 'sharply' improving drug safety. Higher standards, stepped-up monitoring included. News | Follow @FiercePharma

> China blueprints drug-safety improvements. Report

> Teva jacks up prices on Cephalon legacy brands. Story

> Sanofi criticizes study flagging Lantus cancer risk. Article

> FDA scolds Novartis unit for repeat plant violations. News

> Pfizer ordered to pay $72M in Prempro case. Report

Drug Delivery News

> AA battery triggers drug delivery, Stanford U finds. Article

> ViroPharma, Halozyme tackle hereditary angioedema treatment. Story

> Ampio to seek foreign OKs for premature ejaculation drug. More

Biomarkers News

> MicroRNA marks ovarian cancer outcome. News

> Blood test could spot autoimmune kidney attack. Item

> Biomarker test could mean early lung cancer diagnosis. Article

Medical Device News

 Image removed. @FierceMedDev: Tribogenics Raises $2.5 Million to Transform X-Ray Industry. Release | Follow @FierceMedDev

> EyeBrain tech to be used in Parkinson's trial. More

> Oracle urges Thoratec to find buyer. Story

> 5 Innovative Michigan companies. Report

And Finally... Secretary of State Hillary Clinton is sounding the alarm that gene synthesis technology poses a potential threat to the U.S. Officials are worried that new gene technology could clear a path to the development of deadly new bacteria and viruses. Report